RecruitingNCT06533813
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Principal Investigator
- TIZIANO BARBUI, MDFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Enrollment
- 617 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Hematology Center after Prof.R.H. Yeolyan, Yerevan, Armenia
- University of Copenhagen's Roskilde Hospital, Copenhagen, Denmark
- Clinical Investigation Center of the Saint Louis Hospital, Paris, France
- Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, University Medicine Greifswald, Greifswald, Germany
- University Hospital Halle Department of Hematology/Oncology, Halle, Germany
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum, Minden, Germany
- Division of Haematology, Sasson University Hospital Assuta Ashdod, Ashdod, Ben-Gurion University of Negev, Ashdod, Israel
- A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia, Alessandria, Italy
- ASST Papa Giovanni XXIII, SC Ematologia, Bergamo, Italy
- Policlinico S. Orsola - Malpighi, Unità di Ematologia, Bologna, Italy
- Azienda Ospedaliero - Universitaria "Policlinico Vittorio Emanuele" - PO Gaspare Rodolico, Dipartimento di ematologia con Trapianto di midollo Osseo, Catania, Italy
- AOU Careggi di Firenze, Divisione di Ematologia, Florence, Italy
- ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia, Milan, Italy
- Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ematologia, Milan, Italy
- Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo, Milan, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
GlaxoSmithKline
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06533813 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong